Cypress Capital’s Ionis Pharmaceuticals IONS Stock Holding History

Cypress Capital’s Portfolio IONS Stock Details IONS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$451K	Sell	6,000 -4,000	-40%	-$316K	0.13%	69
2025 Q4	$791K	Hold	10,000	–	–	0.22%	56
2025 Q3	$654K	Hold	10,000	–	–	0.19%	60
2025 Q2	$395K	Hold	10,000	–	–	0.11%	68
2025 Q1	$302K	Hold	10,000	–	–	0.09%	69
2024 Q4	$350K	Hold	10,000	–	–	0.1%	65
2024 Q3	$401K	Hold	10,000	–	–	0.1%	67
2024 Q2	$477K	Hold	10,000	–	–	0.12%	67
2024 Q1	$434K	Buy	+10,000	New	+$477K	0.12%	63
2021 Q2	–	Sell	-25	Closed	-$1K	–	95
2021 Q1	$1K	Buy	+25	New	+$1.39K	﹤0.01%	101

Other funds holding IONS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Cypress Capital's IONS Position: Q1 2026 in Review

Cypress Capital reduced its Ionis Pharmaceuticals (IONS) stake by 40% in Q1 2026, selling an estimated $316K and leaving 6,000 shares worth $451K. The position accounts for 0.13% of the portfolio, ranked #69.

Cypress Capital first reported a position in IONS in Q1 2021 and has held it in 10 quarters since. The position peaked at $791K in Q4 2025. 493 funds tracked by Wall St. Rank hold IONS as of Q1 2026.

Cypress Capital held 6,000 shares of Ionis Pharmaceuticals worth $451K as of Q1 2026.
Cypress Capital sold 4,000 Ionis Pharmaceuticals shares in Q1 2026, an estimated $316K.
Ionis Pharmaceuticals made up 0.13% of Cypress Capital's portfolio in Q1 2026, its #69 holding.
Cypress Capital first reported a position in Ionis Pharmaceuticals in Q1 2021 and has held it in 10 quarters since.
Cypress Capital's Ionis Pharmaceuticals position peaked at $791K in Q4 2025.
493 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q1 2026.

Based on Cypress Capital's 13F filing for Q1 2026, filed 28 Apr 2026.